Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study.

Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study.

PURPOSE: Obesity has been associated with an increased risk of advanced and fatal prostate cancer; adipokines may mediate this association. We examined associations of the adipokines leptin and adiponectin with the stage and grade of PSA-detected prostate cancer. METHODS: We conducted a nested case-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burton, A, Martin, R, Holly, J, Lane, J, Donovan, J, Hamdy, F, Neal, D, Tilling, K
Formato:	Journal article
Lenguaje:	English
Publicado:	2013

Ejemplares similares

Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study.
por: Rosario, D, et al.
Publicado: (2008)

Alcohol consumption and PSA-detected prostate cancer risk--a case-control nested in the ProtecT study.
por: Zuccolo, L, et al.
Publicado: (2013)

Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study.
por: Catto, J, et al.
Publicado: (2011)

Suitability of PSA-detected localised prostate cancers for focal therapy: Experience from the ProtecT study
por: Catto, J, et al.
Publicado: (2011)

Association of obesity with prostate cancer: A case-control study within the population-based PSA testing phase of the ProtecT study
por: Dimitropoulou, P, et al.
Publicado: (2011)

Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study.
por: Dimitropoulou, P, et al.
Publicado: (2011)

The ProtecT trial - Evaluating the effectiveness of treatment for clinically localised prostate cancer (ISRCTN20141297)
por: Lane, J, et al.
Publicado: (2004)

Prostate Testing for Cancer and Treatment (ProtecT) feasibility study
por: J. Donovan, et al.
Publicado: (2003-01-01)

The protecT (prostate testing for cancer and treatment) study: Evaluating screening and treatment of clinically localised prostate cancer in the UK
por: Hamdy, F, et al.
Publicado: (2006)

Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies.
por: Lane, J, et al.
Publicado: (2010)

Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.
por: Collin, S, et al.
Publicado: (2009)

Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study).
por: Murad, A, et al.
Publicado: (2011)

ASSOCIATION OF ANTHROPOMETRIC AND LIFESTYLE FACTORS WITH PROSTATE SPECIFIC ANTIGEN (PSA) TRAJECTORIES IN MEN WITH LOCALISED PROSTATE CANCER UNDERGOING ACTIVE MONITORING
por: Burton, A, et al.
Publicado: (2011)

Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial
por: Wade, J, et al.
Publicado: (2015)

Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: The ProtecT three-arm RCT
por: Hamdy, FC, et al.
Publicado: (2020)

Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT
por: Freddie C Hamdy, et al.
Publicado: (2020-08-01)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study
por: Rosario, D, et al.
Publicado: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.
por: Rosario, D, et al.
Publicado: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: Prospective evaluation within ProtecT study
por: Rosario, D, et al.
Publicado: (2012)

Circulating adiponectin and leptin and risk of overall and aggressive prostate cancer: a systematic review and meta-analysis
por: Anya J. Burton, et al.
Publicado: (2021-01-01)

Mortality among nen with advanced prostate cancer excluded from the ProtecT Trial
por: Johnston, T, et al.
Publicado: (2016)

Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial.
por: Er, V, et al.
Publicado: (2017)

Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study.
por: Mills, N, et al.
Publicado: (2003)

The Prostate Testing for Cancer and Treatment (ProtecT) study: what have we learnt?
por: Hamdy, F
Publicado: (2017)

Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study).
por: Donovan, J, et al.
Publicado: (2003)

Associations of lifestyle factors and anthropometric measures with repeat PSA levels during active surveillance/monitoring.
por: Burton, A, et al.
Publicado: (2012)

A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study).
por: Mills, N, et al.
Publicado: (2006)

Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study
por: Adams, Charleen D., et al.
Publicado: (2018)

Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful?
por: Harrison, S, et al.
Publicado: (2016)

Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.
por: Lane, A, et al.
Publicado: (2016)

Experiences and decision processes during PSA testing and prostate biopsy: A qualitative study
por: Avery, K, et al.
Publicado: (2007)

The value of repeat serum PSA measurements in the detection of prostate cancer - Experience from the feasibility phase of the UK protect study
por: Hamdy, F, et al.
Publicado: (2006)

PTGS2-899G>C and prostate cancer risk: a population-based nested case-control study (ProtecT) and a systematic review with meta-analysis.
por: Murad, A, et al.
Publicado: (2009)

Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial
por: S. Sanghera, et al.
Publicado: (2020-10-01)

A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial
por: Donovan, JL, et al.
Publicado: (2017)

Decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial.
por: Avery, K, et al.
Publicado: (2008)

A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: findings from a population-based, case-control study (the ProtecT study).
por: Murad, A, et al.
Publicado: (2010)

The ProtecT trial: Analysis of the patient cohort, baseline risk stratification and disease progression
por: Young, GJ, et al.
Publicado: (2020)

Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study
por: Leal, J, et al.
Publicado: (2018)

Metabolic imbalance and prostate cancer progression.
por: Burton, A, et al.
Publicado: (2010)